BNET Industries
Market Cap:$943.7M
Last Fiscal Year Sales:$294.2M
- Public
- US
Dow Jones Description
PDL BioPharma, Inc. pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and autoimmune diseases.
Interim Chief Executive OfficerL. Patrick Gage
Number of Employees 6
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
Recent Events
-
PDL BioPharma Announces Record Date for October 1 Dividend Payment
-
BUYINS.NET: PM, T, UMC, BMY, SWIM, HIG: Highest Net Sell Volume and Negative Price Friction...
-
PDL BioPharma Guides Above Estimates
-
Market Maker Surveillance Report. Top 6 Highest Net Buy Volume With Lowest Price Friction Stocks...
-
PDL BioPharma Announces First Quarter 2009 Financial Results
-
PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer
-
PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting...
-
PDL BioPharma names Karen Wilson VP of finance and principal accounting officer - Quick Facts
-
PDL BioPharma appoints VP finance, principle accounting officer
-
PDL BioPharma Elects Frederick Frank and Jody Lindell to Its Board of Directors
-
BUYINS.NET: Market Maker Surveillance Report. Highest Net Sell Volume and Negative Price Friction Stocks For...
-
PDL Biopharma shares rise on 4Q results, outlook
-
Facet Biotechnology to cut 78 workers
News & Analysis
Filter by
pdl biopharma inc. - All News and Analysis
PDL BioPharma, Inc. Q1 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Operator instructions Your first question comes from Geoff Meacham with JP Morgan. Terry Kline – JP Morgan Hi guys, thanks for taking the question. This is Terry Kline for Geoff today. Just a question on potential to monetize the royalty stream, I guess as you see the...
PDL BioPharma: Past, Present and Future
Jeff Borack submits: PDL BioPharma PDLI was a biotech research and development company until recently when it spun-off the research and development portion of the business, leaving behind six employees and seven patents to protect. The patents protect PDLI’s antibody humanization technology, and will be expiring between 2013-2014, at...
PDL BioPharma, Inc. Q4 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. Operator instructions We will go first to Joel Sendek with Lazard Capital Markets. Joel Sendek – Lazard Capital Markets Thanks. A couple of questions, the first on the MedImmune litigation. As they have been paying royalties for over 10 years now, it seems to me...
What Does Seth Klarman See in Facet Biotech?
Dean Morel submits: I originally disagreed with this Seeking Alpha article which claimed Facet Biotech Inc FACT was a current Seth Klarman favorite. However, upon more research it appears Klarman, the founder of Baupost Group, does indeed see value in this biotech spin-off from PDL BioPharma Inc PDLI. In my...
PDL BioPharma Inc. Q3 2008 Earnings Call Transcript
Earnings Call ExcerptPDL BioPharma Inc. PDLI Q3 2008 Earnings Call November 6, 2008 4:30 pm ET Executives Ami Knoefler - Head of Corporate and IR Dr. Mark McCamish - Senior Vice President and Chief Medical Officer Faheem Hasnain – President and CEO Andrew Guggenhime - CFO ...
15 Value Hedge Funds Portfolio Update
Mebane Faber submits: Are the top value hedge funds going to beat the market every quarter, or just outperform when the market is going up? Maybe we should ask Will Ferrell, errr, I mean Robert Goulet: by Mebane Faber
Bristol-Myers Ponies Up for Elotuzumab
Eben Tessari submits: Bristol-Myers Squibb BMY and PDL BioPharma PDLI announced an agreement for the global development and commercialization of PDL BioPharma’s anti-CS1 antibody, elotuzumab (HuLuc63), currently in Phase I development for multiple myeloma. Does someone have some cash burning a hole in their knickers? BMS has been on...
Seth Klarman, Meryl Witmer and Marty Whitman - Q2 2008 Portfolio Moves
Davy Bui submits: Seth Klarman’s Baupost Group continues its move into the healthcare sector asevidenced by the latest Q2 13F-HR filing: Baupost opened big positions in UnitedHealth Group UNH and Liberty Media. The UNH position complements last quarter’s WLP position, which was augmented 24% in Q2. Additionally, by my...
New Analyst Reports for NOVA BIOSOURCE FUELS INC, ENDO PHARMACEUTICALS HOLDINGS INC, HYDROGENICS CORPORATION, and PDL BIOPHARMA INC
MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for NOVA...
PDL BioPharma Q2 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. And your first question comes from Joel Sendek. Joel Sendek - Lazard Capital Markets Hi, thanks. On SG&A, just a couple questions here. Tell us again how much, I just missed it, was reclassified from R&D to G&A with the dollar amount...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| L. Patrick Gage | Interim Chief Executive Officer |
| Andrew L. Guggenhime | Senior Vice President and Chief Financial Officer |
| Mark McCamish | Senior Vice President and Chief Medical Officer |
| Richard Murray | Executive Vice President and Chief Scientific Officer |
| Brett Schmidli | Senior Vice President, Technology Operations |
| Douglas Ebersole | Senior Vice President & Secretary |
| Jaisim Shah | Senior Vice President, Marketing and Business Affairs |
| Behrooz Najafi | Vice President, Information Technology |
| Cynthia Shumate | Vice President, Intellectual Property |
| Debbie Law | Vice President, Research |
| Eric Emery | Vice President, Manufacturing |
| George T. Jue | Vice President, Finance & Controller |
| Graeme Currie | Vice President, Clinical Operations |
| Helen S. Kim | Vice President, Marketing |
| Julie Badillo | Vice President, Biopharmaceutical Program Management |
| Karen Wilson | Vice President, Finance & Principal Accounting Officer |
| Laurie Torres | Vice President, HR |
| Lyn D. Olson | Vice President, Quality & Compliance |
| Maninder Hora | Vice President, Process Development |
| Mark P. Backer | Vice President, Technology Development |
| Robert Kirkman | Vice President, Business Development & Corp Communications |
| Robert Stagg | Vice President, Regulatory Affairs & Safety |
| William R. Benjamin | Vice President, Res & Clinical Technology |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Karen A. Dawes | Chairman |
| Bradford S. Goodwin | Board of Directors |
| Frederick Frank | Board of Directors |
| Jody S. Lindell | Board of Directors |
| Jon S. Saxe | Board of Directors |
| Joseph Klein III | Board of Directors |
| Laurence Jay Korn | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Interim Chief Executive Officer | Current |
| Flagship Ventures | Venture Partner | Current |
| Adnexus | Chairman of the Board | Current |
| Acceleron Pharma Inc | Board of Directors | Current |
| Functional Genetics, Inc. | Board of Directors | Current |
| Alvine Pharmaceuticals, Inc. | Director | Current |
| Biotechnology Institute | Board of Directors | Current |
| The Philadelphia Orchestra Association | Board of Directors | Current |
| PDL BioPharma, Inc. | Board of Directors | Current |
| Warburg, Pincus, LLC | Life Sciences Advisory Board | Current |
| Genetics Institute, Inc. | President | Former |
| Wyeth Research | President | Former |
| Genetics Institute, Inc. | Chief Operating Officer | Former |
| Wyeth Research | Chief Scientific Officer | Former |
| Wyeth Research | Senior Vice President, Science and Technology | Former |
| Hoffmann-La Roche Inc. | Vice President, Exploratory Research | Former |
| Genetics Institute, Inc. | R&D Head | Former |
| Hoffmann-La Roche Inc. | Research Management | Former |
| Neose Technologies, Inc. | Chairman | Former |
| PDL BioPharma, Inc. | Chairman | Former |
| Wyeth Research | Director | Former |
| University of Chicago | Ph.D. In Biophysics | Former |
| University of Chicago | Bachelors Degree In Physics | Former |
| Massachusetts Institute of Technology | B.S. in Physics | Former |
| Acceleron Pharma Inc | Chairman of the Board | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Senior Vice President and Chief Financial Officer | Current |
| Neoforma Inc. | CFO | Former |
| Wells Fargo & Company | Assistant Vice President | Former |
| Northwestern University | Master of Management degree | Former |
| Middlebury College | Bachelor of Arts degree in international politics and economics | Former |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Senior Vice President and Chief Medical Officer | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Executive Vice President and Chief Scientific Officer | Current |
| PDL BioPharma, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Senior Vice President, Technology Operations | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Senior Vice President & Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Senior Vice President, Marketing and Business Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Information Technology | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Intellectual Property | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Research | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Manufacturing | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Finance & Controller | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Clinical Operations | Current |
| Dayspring Pharma | Board of Directors | Current |
| ESP Pharma, Inc. | Vice President | Former |
| ESP Pharma, Inc. | Senior Director | Former |
| Gilead Sciences, Inc. | Director of Clinical Research | Former |
| Hepsera | Former | |
| Aston University | Ph.D. | Former |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Biopharmaceutical Program Management | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Finance & Principal Accounting Officer | Current |
| Monogram Biosciences, Inc. | Chief Financial Officer | Former |
| Novare Surgical Systems, Inc. | Chief Financial Officer & Vice President, Operations | Former |
| Deloitte & Touche LLP | Senior Manager | Former |
| University of California, Berkeley | B.S., Business | Former |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Quality & Compliance | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Process Development | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Technology Development | Current |
| Organization | Position | Status |
|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | Vice President | Current |
| PDL BioPharma, Inc. | Vice President, Business Development & Corp Communications | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Regulatory Affairs & Safety | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Vice President, Res & Clinical Technology | Current |
| Organization | Position | Status |
|---|---|---|
| ESP Pharma, Inc. | Current | |
| PDL BioPharma, Inc. | Chairman | Current |
| Repligen Corporation | Board of Directors | Current |
| Depomed, Inc. | Board of Directors | Current |
| Genetics Institute, Inc. | Vice President, Commercial Operations | Former |
| Pfizer Inc. | Vice President | Former |
| Bayer Corporation | Former | |
| Harvard Business School | MBA degree | Former |
| Simmons College | degrees in English | Former |
Bradford S. Goodwin joined us as a director in January 2007. Mr. Goodwin is currently President and CEO of Keren Pharmaceuticals, Inc. and director of Facet Biotech Corporation. His prior public company board services include PDL BioPharma and CoTherix, Inc. From 2001 to 2006, he was Chief Executive Officer and Director of Novacea, Inc., a publicly-held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for cancer. Prior to Novacea, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, a company focused on pharmaceutical product licensing and development. Before starting Collabra, he held various senior executive positions with Genentech, Inc., including Vice President of Finance. After becoming a CPA while working as an auditor at PricewaterhouseCoopers, he served on expert advisory committees of the American Institute of Certified Public Accountants, the Financial Accounting Standards Board and the International Accounting Standards Board. Mr. Goodwin holds a BS in business administration from the University of California, Berkeley.
| Organization | Position | Status |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | Board of Directors | Current |
| PDL BioPharma, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Harvard School of Public Health | Advisory Director | Current |
| Yale School of Management | Advisory Director | Current |
| Landec Corporation | Vice Chairman and Director of Lehman Brothers | Current |
| PureTech Ventures | Senior Advisor | Current |
| Salk Institute | Director | Current |
| Hemobiotech, Inc. | Board of Directors | Current |
| Orbimed Advisors, LLC | Chairman of The Board | Current |
| Irvington Institute for Immunological Research | Chairman | Current |
| Predix Pharmaceuticals Holdings, Inc. | Chairman of The Board | Current |
| Celtic Pharma | Vice Chairman | Current |
| Egeen Intl. Corp. | Vice Chairman | Current |
| Kinemed, Inc | Vice Chairman | Current |
| Hemobiotech, Inc. | Vice Chairman of Lehman Brothers | Current |
| New York Society of Security Analysts | Board of Directors | Current |
| Business Engine, Inc. | Director | Current |
| PDL BioPharma, Inc. | Board of Directors | Current |
| Diagnostic Products Corporation | Director | Current |
| eSoft, Incorporated | Director | Current |
| Institute for Systems Biology | Director | Current |
| Ophthalmopharma AG. | Board of Directors | Current |
| Harvard School of Public Health | Advisory Board Member | Current |
| 1-800-Doctors, Inc. | Director | Current |
| Pharmaceutical Product Development, Inc. | Director | Current |
| EPIX Pharmaceuticals, Inc. | Board of Directors | Current |
| EPIX Pharmaceuticals, Inc. | Board of Directors | Current |
| New York Society of Security Analysts | Member | Current |
| Smith Barney | Vice President | Former |
| Lehman Brothers Holdings Inc. | Senior Managing Director | Former |
| Lehman Brothers Holdings Inc. | partner | Former |
| Swedish American Life Science | Board of Directors | Former |
| Lehman Brothers Holdings Inc. | Vice Chairman | Former |
| Lehman Brothers Holdings Inc. | Director | Former |
| Smith Barney | Director | Former |
| Stanford University | MBA | Former |
| Stanford Graduate School of Business | MBA | Former |
| Yale University | B.A. | Former |
| Organization | Position | Status |
|---|---|---|
| First Republic Bank | Director | Current |
| The Cooper Companies, Inc. | Board of Directors | Current |
| PDL BioPharma, Inc. | Board of Directors | Current |
| KPMG International | partner | Former |
| Stanford University | M.B.A. | Former |
| Stanford University | B.A | Former |
| Organization | Position | Status |
|---|---|---|
| Needham Capital Partners | Limited Partner | Current |
| Ptv Sciences | Director of the Company | Current |
| Hoffmann-La Roche Inc. | Head of Patent Law | Current |
| Ask About Patents | Current | |
| ESP Pharma, Inc. | Current | |
| Sciele Pharma, Inc. | Audit Committee Chairman | Current |
| SciClone Pharmaceuticals, Inc. | Chairman | Current |
| Vistagen, Inc. | Chairman | Current |
| Entelos, Inc. | Chairman of the Board | Current |
| PDL BioPharma, Inc. | Board of Directors | Current |
| DURECT Corporation | Board of Directors | Current |
| Astex Therapeutics Limited | Board of Directors | Current |
| InSite Vision Incorporated | Director | Current |
| Id Biomedical Corp | Director | Current |
| Incyte Genomics, Inc. | Director | Current |
| Barofold, Inc | Board of Directors | Current |
| Questcor Pharmaceuticals, Inc. | Director | Current |
| M Stage Pharmacueticals, Inc | Board of Directors | Current |
| Synergen, Inc. | Chief Executive Officer | Former |
| Synergen, Inc. | President | Former |
| PDL BioPharma, Inc. | President | Former |
| Roche | Vice President, Licensing & Corporate Development | Former |
| Hoffmann-La Roche Inc. | Vice President of Licensing & Corporate Development | Former |
| Iconix Pharmaceuticals, Inc. | Limited Partner | Former |
| Point Biomedical Corporation | Limited Partner | Former |
| Institutional Venture Partners | Executive-In-Residence | Former |
| Synergen, Inc. | Director | Former |
| Iconix Pharmaceuticals, Inc. | Director | Former |
| PDL BioPharma, Inc. | Director | Former |
| SciClone Pharmaceuticals, Inc. | Director | Current |
| The George Washington University | J.D. | Former |
| New York University | L.L.M. | Former |
| New York University School of Law | Ll.M. | Former |
| Carnegie Mellon University | Bsche | Former |
Joseph Klein III was elected a director of the Company in July 2007. Mr. Klein currently serves as Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. Since September 2003, Mr. Klein has also served as a Venture Partner of Red Abbey Venture Partners, LP, a life sciences private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems, from June 1999 until it merged with WebMD Corporation in September 2000. In the 10 years prior to joining Medical Manager Corporation, Mr. Klein was a portfolio manager and securities analyst at T. Rowe Price Associates, Inc. and The Kaufmann Fund, Inc. Mr. Klein serves on the Board of Directors of BioMarin Pharmaceutical Inc., Isis Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Savient Pharmaceuticals, Inc., each of which is a publicly traded company. Mr. Klein received a B.A. in economics from Yale University and an M.B.A. from the Stanford Graduate School of Business.
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| PDL BioPharma, Inc. | Board of Directors | Current |
Executive News
-
REG-Entelos Inc. Shareholders Approve Delisting from AIM
-
REG-Entelos Inc. Entelos, Inc. Proposed Delisting from AIM
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
PDL
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
